LB Fernandes, JL Ellis and BJ Undem
Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland 21224.

Human bronchial rings were contracted with histamine (3 microM), and inhibitory responses were obtained with electrical field stimulation (EFS) in the presence of propranolol (1 microM), atropine (1 microM), and indomethacin (3 microM). These nonadrenergic noncholinergic (NANC) relaxations were frequency-dependent (1 to 32 Hz) and inhibited by either tetrodotoxin or Nw-nitro-L-arginine (L-NNA, 100 microM). The selective cAMP-specific phosphodiesterase (PDE) type IV inhibitors rolipram (3 microM) and Ro 20-1724 (3 microM) significantly potentiated NANC relaxations at each frequency of stimulation. The selective cGMP- specific PDE type V inhibitor zaprinast (3 microM) failed to significantly alter the maximal NANC response, but it caused a slight potentiation of the response at lower frequencies. The adenylyl cyclase stimulant forskolin, the nitric oxide donor compound 3- morpholinosydnonimine (SIN-1), and the guanylyl cyclase stimulant sodium nitroprusside caused concentration-dependent relaxation of histamine-contracted airway smooth muscle. Rolipram significantly potentiated the relaxation elicited by forskolin. Rolipram also potentiated responses to SIN-1 and sodium nitroprusside. Considered together these data support the hypothesis that cAMP plays a facilitory role in NANC relaxation of the human bronchi.

This article has been cited by other articles:

				A. M. Hamad, A. Clayton, B. Islam, and A. J. Knox Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L973 - L983. [Abstract] [Full Text] [PDF]

				M. M. Billah, N. Cooper, M. Minnicozzi, J. Warneck, P. Wang, J. A. Hey, W. Kreutner, C. A. Rizzo, S. R. Smith, S. Young, et al. Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline Carboxamide (SCH 351591), a Novel, Orally Active Phosphodiesterase 4 Inhibitor J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 127 - 137. [Abstract] [Full Text] [PDF]

				M. Aoki, S. Yamamoto, M. Kobayashi, K. Ohga, H. Kanoh, K. Miyata, K. Honda, and T. Yamada Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 165 - 173. [Abstract] [Full Text]

				K. Fujii, H. Kohrogi, H. Iwagoe, J. Hamamoto, N. Hirata, E. Goto, O. Kawano, K. Wada, S. Yamagata, and M. Ando Novel Phosphodiesterase 4 Inhibitor T-440 Reverses and Prevents Human Bronchial Contraction Induced by Allergen J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 162 - 169. [Abstract] [Full Text]

				E. Ekblad and F. Sundler Motor Responses in Rat Ileum Evoked by Nitric Oxide Donors vs. Field Stimulation: Modulation by Pituitary Adenylate Cyclase-Activating Peptide, Forskolin and Guanylate Cyclase Inhibitors J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 23 - 28. [Abstract] [Full Text]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]